Kura Oncology announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. Dr. Vasconcelles currently serves as a Senior Advisor to the Life Sciences team at Frazier Healthcare Partners.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology to Participate in Cantor Global Healthcare Conference
- Kura Oncology reports Q2 EPS (59c), consensus (63c)
- Kura Oncology Reports Second Quarter 2024 Financial Results
- Kura Oncology announces FDA clearance of IND application for ziftomenib
- Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)